Phase II Study of Modified Short-Course Radiation with CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
Led by Sir Run Run Shaw Hospital · Updated on 2025-01-09
32
Participants Needed
1
Research Sites
88 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment approach for patients with microsatellite stable MSS middle and low rectal cancer. This open-label, phase II clinical trial involves 32 patients and aims to assess the effectiveness of modified short-course radiation combined with chemotherapy CAPOX and a PD-1 inhibitor called Tislelizumab. The main goal is to measure the rate of complete tumor response after treatment, while also examining organ preservation, tumor shrinkage, long-term outcomes, and side effects.
Participants will receive a specialized short-course radiation targeting only the tumor bed without affecting surrounding lymph nodes. This radiation is given as 25 Gy over 5 sessions. Alongside radiation, patients will be treated with chemotherapy drugs oxaliplatin and capecitabine, plus Tislelizumab, a PD-1 antibody. These therapies are given in cycles every 3 weeks for a total of four cycles. After completing treatment, patients will undergo surgery to remove the tumor area.
During the study, participants will be closely monitored through various assessments including tumor response and regression evaluation within 10 days after surgery. Researchers will also track local recurrence, disease-free survival, overall survival, adverse effects, and quality of life for up to five years post-surgery. Specific questionnaires and scoring systems like QLQ-CR29, QLQ-C30, and the Wexner score will be used to assess patient well-being and rectal function throughout the follow-up period.
CONDITIONS
Brief Title
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
Research Team
Z
Zhangfa Song, M.D, PH.D
C
Cheng Cai, master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients willing to preserve the anus and receive neoadjuvant therapy
Male or female aged 18 to 75 years
Diagnosis of low rectal cancer within 10 cm from tumor to anal verge confirmed by pelvic MRI and anorectoscopy
Clinical stage cT2N+M0 or cT3-4aN0/+M0 with lymph nodes limited to mesorectum and negative circumferential resection margin
Histologically confirmed rectal adenocarcinoma with MSI-L or MSS status or pMMR by immunohistochemistry
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
No previous anti-tumor treatment, immunotherapy, or pelvic radiation
Adequate blood, liver, kidney, thyroid, and heart function meeting specified laboratory criteria
Signed informed consent form
You will not qualify if you...
History of malignant tumors other than rectal cancer
Presence of distant metastases
Positive internal or external iliac lymph nodes by MRI or CT
Obstruction, perforation, or bleeding requiring emergency surgery
Severe concomitant diseases with estimated survival less than or equal to 5 years
Allergy to any therapy component
Poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous adenocarcinoma
Use of immunosuppressive or systemic hormone therapy for immunosuppression within 1 month before treatment
Participation in another interventional clinical trial or use of experimental drugs within 30 days before screening
Conditions like alcoholism, drug abuse, serious illnesses, or severe lab abnormalities leading to study termination
Congenital or acquired immune deficiency such as HIV infection
Vulnerable groups including mentally ill, cognitively impaired, critically ill patients, minors, pregnant or lactating women, illiterate individuals
Other conditions deemed unsuitable by investigators
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Approximately 12 weeks (4 cycles, 3 weeks each)
Participants receive modified short-course radiation targeting the tumor bed combined with CAPOX chemotherapy and tislelizumab immunotherapy. CAPOX and tislelizumab are administered every 3 weeks for 4 cycles.
Multiple visits every 3 weeks for 4 cycles during treatment
Surgery
Duration - Within 10 days after treatment completion
Participants undergo total mesorectal excision surgery following completion of radiation and drug treatment.
1 surgical procedure
Follow-up
Duration - Up to 5 years
Participants are monitored for tumor response, local recurrence, disease-free survival, overall survival, adverse effects, and quality of life assessments after surgery.
Visits at baseline and months 3, 6, 12, 24, 36, and 60 after surgery
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluation of Precision Partial Intersphincteric Resection Compared to Traditional Surgery for Ultra-low Rectal Cancer
Phase II Study of Modified Short-Course Radiation with CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
Comparing Low Anterior Resection With or Without Preventive Stoma in Adults with Low-Risk Rectal Cancer
A Multicenter Randomized Trial Evaluating Safety and Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Node-sparing modified short-course Radiotherapy Combined with CAPOX and Tislelizumab for locally Advanced MSS of Middle and low rectal Cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial.